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Background. Liver transplantation (LTx) for hepatoblatoma appears to be increasing. Favorable tumor
histology is increasingly linked to survival after surgical resection and could also determine
posttransplantation outcomes.
Methods. To evaluate national trends in tumor and LTx incidence as the basis for observations at some
LTx centers, and determinants of survival after LTx for hepatoblastoma, we queried the National
Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) registry representing 9.451% of
the U.S. population (1975–2007), the United Network for Organ Sharing (UNOS, 1988–2010,
n = 332), and Children’s Hospital of Pittsburgh database (CHP, 1987–2011, n = 35).
Results. In the United States, hepatoblastoma cases increased 4-fold, LTx for hepatoblastoma increased
20-fold, and hepatoblastoma surpassed other unresectable liver malignancies requiring LTx by nearly
3-fold. Actuarial 5-year patient survival exceeded 75%. Recurrences in 16% were greater after
segmental LTx in the total U.S. experience (P = .049). At CHP, 5 children died from recurrences (n = 4)
and sepsis (n = 1). Tumors were epithelial (57%) or mixed epithelial-stromal (42%), Children’s On-
cology Group stage III (77%) or IV (23%). Recurrences were related to previous pulmonary metastases
(P = .016), and tumor necrosis <50% (P = .013), but not to small cell undifferentiated tumor histology
(P = NS). Hepatic artery thrombosis was more common after LTx for hepatoblastoma compared with
nonmalignant indications (P = .0089). Thirty-three children received pre-LTx chemotherapy, 88.6%
with cisplatin, and 85.7% received post-LTx chemotherapy.
Conclusion. Outcomes after LTx for hepatoblastoma may benefit from improved detection and treatment of
pretransplantation metastases, adequate tumor lysis after chemotherapy, and perioperative antithrombotic
agents but are unaffected by undifferentiated tumor histology. (Surgery 2013;153:150-9.)From the Starzl Transplantation Institute,a University of Pittsburgh Medical Center (UPMC), Department of
Pathology,b Hillman Center for Pediatric Transplantation,c Children’s Hospital of Pittsburgh of UPMC, and
Division of Hematology/Oncology,d Department of Pediatrics, University of Pittsburgh School of Medicine and
Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PAHEPATOBLASTOMA is the most common liver malig-
nancy in children and has high cure rates if it can
be resectedoperatively.Uresectable hepatoblastomad for publication November 6, 2012.
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Open access under CC BY-NC-ND license.confined to the liver can be cured with liver trans-
plantation (LTx).1 To facilitate timely LTx, the
UnitedNetwork forOrgan Sharing (UNOS)permits
a greater listing priority for children with this malig-
nancy.2 Since 2009, the Children’s Oncology Group
also has recommended referral of such children to
centers with expertise in LTx, preferably by the
timeof the secondcycle of chemotherapy.3However,
transplantation centers have experienced increased
referral for unresectable neoplasms before 2009. In
2000, we described post-LTx outcomes in 12 chil-
dren with hepatoblastoma accrued over 2 decades
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twice as many additional children have received
LTx for this malignancy at our center, making it
the largest such series at a singleU.S. center. This ob-
servation led us to ask whether the incidence of this
malignancy and of LTx for this malignancy has in-
creased in the United States, thereby posing addi-
tional competition for precious pediatric liver
grafts, and whether increased application of LTx
has improved posttransplantation outcomes for
this malignancy.
Because this information is not available in any
single database, we queried 2 large national data-
bases to confirm our observations and answer
these questions. Recent studies also show unfavor-
able outcomes after liver resection for hepatoblas-
toma in the presence of small cell undifferentiated
(SCU) tumor histology and inadequate tumor
necrosis after chemotherapy.5-8 The influence of
these risk factors on posttransplantation survival
is less established and is now evaluated in our
single-center LTx experience along with other on-
cologic and technical risk factors. Our findings ar-
gue for a coordinated effort to study post-LTx
outcomes prospectively relative to those after liver
resection for hepatoblastoma, and revisit current
referral and management practices in higher-risk
tumors in an ongoing effort to improve oncologic
outcomes and utilization of a precious resource.
METHODS
Data sources. The incidence of hepatoblastoma
in theUnited States from 1975 to 2007 was obtained
from Surveillance, Epidemiology and End Results
(SEER)/National Cancer Institute database using
SEER*Stat software (www.seer.cancer.gov/seerstat)
version 6.5.2. SEER compiles cancer statistics in
the United States using incidence, survival, and
prevalence from 9 registries. Between 1975 and
2007, the regions served by these registries included
Atlanta, Connecticut, Detroit, Hawaii, Iowa, New
Mexico, San Francisco-Oakland, Seattle-Puget
Sound, and Utah and represented 9.451% of the
U.S. population. The incidence of LTx for hepato-
blastoma in the United States was obtained from
the UNOS database for the period January 1, 1988
to December 31, 2010. Data were obtained for all
U.S. centers for patient and graft survival and the in-
cidence of recurrence and retransplantation. Rec-
ords of children with hepatoblastoma who
received LTx at the Children’s Hospital of Pitts-
burgh (CHP) database were queried in the Elec-
tronic Data Interface for Transplantation. All
children ages <18 years of age who received LTx
for hepatoblastoma between December 1987 andApril 2011 were queried for age and sex, oncologic
history including previous resections, a-fetoprotein
(AFP) levels, and pre- and post-LTx chemotherapy
under institutional review boardexempt protocol
07110120. Additional LTx-related variables evalu-
ated were type of allograft whether cadaveric or liv-
ing donor, whole liver or segmental graft, whether
standard hepatectomy (which removes the recipi-
ent’s retrohepatic vena cava) or the cava-sparing
piggyback LTx procedure was performed, donor
age, cold and warm ischemia time, patient and graft
survival, and follow-up laboratory tests. Tumor and
allograft histopathology were reviewed by a single
pathologist (S.R.). Variables analyzedwere size of tu-
mor, histological characteristics including presence
of the SCU histology and extent of tumor necrosis,
positive margins or nodes, and macroscopic or
microscopic vascular invasion.
Post-LTx outcomes evaluated were early vascular
complications, and the incidence and severity of
acute cellular rejection. These post-LTx outcomes
were evaluated in the most recent 25 LTx for hepa-
toblastoma at CHP and compared with 44 other LTx
for nonmalignant indications performed contempo-
raneously. Both groups received tacrolimus and ste-
roid immunosuppression during a time interval that
began after immunosuppression practices were stan-
dardized at CHP. Practiced currently, this standard
consists of lymphocyte depleting immunosuppres-
sion for all except those with malignancy or recent
infections. Thus, our conclusions are not con-
founded by variable immunosuppressive regimens.
Statistical analysis. Descriptive statistics were gen-
erated for demographic variables. Categorical data
were expressed as counts (percentage), and contin-
uous data as mean ± SD. Between-group compari-
sons of categorical data were performed with the
Fisher exact tests or Pearson v2 tests, where applica-
ble. Continuous variables were compared with t-tests
for 2 independent samples or Mann-Whitney tests,
whenever assumptions of normal distribution were
violated in small samples. Actuarial patient and graft
survival were determined by use of the Kaplan-Meier
method. Statistical analyses were performed using
the Statistic Package for Social Sciences forWindows
software / SPSS (version 15, SPSS Inc., Chicago, IL).
RESULTS
Increasing U.S. incidence of hepatoblastoma.
Incidence rates for hepatoblastoma per 100,000
population were age-adjusted to the 2000 U.S. stan-
dard population (19 age groups: Census P25-1130)
standard; confidence intervals (Tiwarimod)are 95%
for rates. The incidence rate increased almost 3-fold,
from 0.014 to 0.039 (Fig 1,A). For the regions served
Fig 1. (A) Incidence of hepatoblastoma (HBL) in pedi-
atric population from 1975 to 2007. Rates are per
100,000 and age-adjusted to the 2000 U.S. standard
population. Data obtained from SEER/National Insti-
tute of Cancer (NIC). (B) Number of pediatric LTx
for unresectable hepatoblastoma in the United States
from 1988 to 2010. (C) Relative proportions of LTx
for hepatoblastoma and other liver malignancies at
non-CHP centers (1988 to 2010). Based on Organ
Procurement and Transplantation Network data as of
April 1, 2011.
Surgery
February 2013
152 Cruz et alby the 9 registries reporting to SEER, these rates were
based on 11 new cases in 2007 compared with only 3
new cases in 1975, from 9.5%of theU.S. population.
Extrapolated to the 10-fold larger U.S. population,
the estimated numbers of new cases of hepatoblas-
toma increased almost 4-fold during the 32-year ob-
servation period, from an estimated 30 new cases in
1975 to an estimated 117 new cases in 2007(Supplementary Table 1). During this period, the
U.S. population increased by 38.5%.
Increasing U.S. incidence of LTx for hepato-
blastoma. Between 1988 and 2010, 332 children
received LTx for unresectable hepatoblastoma in
the United States, including 33 from our center.
Annual numbers increased almost 20-fold, from 2
cases in 1988 to 38 cases in 2010, with 153 LTx
(46%) occurring in the last 5 years (Fig 1, B).
Between 1989 and 1993, #2% LTx each were per-
formed for hepatoblastoma and nonhepatoblas-
toma liver malignancies. In 2010, 7.5% LTx were
performed for hepatoblastoma compared with
2.8% for other malignancies (Fig 1, C and
Supplementary Table 2). For 332 LTx performed
in the United States, recipients were predomi-
nantly male (60.8%), white (67.8%), <5 years old
(79.5%), received cadaveric grafts (84.9%), and
were not hospitalized at the time of transplanta-
tion (75.9%). The waiting time on the list was
72 ± 112 days (Supplementary Table 3).
Of the estimated annual numbers of hepato-
blastoma cases, an increasing proportion appears
to have been referred for LTx from 5% in early
1990s to about 10% from 1999 onward, reaching
20% after 2004 (Supplementary Table 1). Despite
this apparently increased referral for LTx after
1999, posttransplantation survival is similar for
the 2 periods (P = .59, NS).
Survival statistics of LTx for hepatoblastoma in
the United States. For 332 LTx performed for
unresectable hepatoblastoma in the United States
between 1988 and 2010, actuarial 1-, 3-, and 5-year
patient survival was 84%, 75.7%, and 73.1%, re-
spectively (Fig 2). Actuarial 1-, 3-, and 5-year graft
survival was 80.2%, 70.7%, and 68.1%, respectively
(Fig 2). Recurrent hepatoblastoma occurred in 53
children (15.9%). Recurrences were more fre-
quent after segmental cadaveric or living donor
grafts compared with cadaveric whole liver grafts
(20.7 vs 12.5%, P = .049). Seventy children died,
46 due to recurrences, 16 due to operative compli-
cations or sepsis, and 8 due to unknown causes
(Supplementary Table 4). Retransplantation was
performed in 33 of 332 children. The most com-
mon indication for retransplantation was vascular
thrombosis (60.6%), followed by primary nonfunc-
tion (15.2%), and rejection (9.1%).
CHP experience. Patient characteristics. Thirty
five children, 21 males and 14 females, received
LTx for hepatoblastoma at CHP during a 23-year
span from 1987–2011 (Table I). Three-fourths of
these children received cadaveric allografts consist-
ing of whole grafts in 20 and reduced-size left lat-
eral segmental liver grafts in seven children. All 8
Fig 2. Kaplan-Meier curves for Patient and graft survival
for 332 children who received LTx in the United States
between 1988 and 2010 (Based on Organ Procurement
and Transplantation Network data as of April 1, 2011).
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segments. The donors were 5 mothers and 3 fa-
thers with a median age of 33 years (range, 25–
40 years). Compared with recipients of cadaveric
allografts, LD-LTx recipients were also younger
(1.8 ± 1.0 years vs 3.3 ± 1.4 years, P = .008), and un-
derwent transplantation significantly earlier after
diagnosis of hepatoblastoma (5.4 ± 1.9 months vs
8.6 ± 4.9 months, P = .010, Table I).
Tumor characteristics pretransplantation. The tu-
mor was centrally located and/or showed vessel
invasion in 19 children (54.3%), was multifocal or
bilobar in 11 (31.4%), and consisted of recurrent
or residual tumor in 5 children who underwent
previous right liver lobectomies (14.3%). Resec-
tion also was attempted and abandoned in 4 of
19 children with centrally located mass. Therefore,
9 children were referred for transplantation
after operative exploration or liver resection. Eightchildren presented with stage IV disease consisting
of lung metastases before LTx (Table II). Metasta-
ses were successfully resected in 2 and resolved
with chemotherapy before LTx in 6 children.
The median AFP at the time of diagnosis was
100,000 ng/mL (range, 238–851,000 ng/mL)
and greater at the time of diagnosis in LD-LTx re-
cipients (P = .002). The AFP decreased to 2,381
ng/mL (range, 4–319,000) at time of LTx and
was not different between cadaveric and LD-LTx
(P = .652, NS, Table I).
Chemotherapy. Thirty-three children received neo-
adjuvant chemotherapy. Chemotherapy data are not
available for 2 of 35 children. Although the chemo-
therapy protocol varied over the 23-year period, 32
(91%) children received cisplatin-based pretrans-
plantation chemotherapy. Thirty children (85.7%)
received adjuvant chemotherapy after transplanta-
tion. The median numbers of chemotherapy cycles
before and after LTxwere 4 (range, 4–7) and2 cycles
(range, 1–5), respectively. During our earlier expe-
rience, 5 patients who did not respond to systemic
chemotherapy also received intra-arterial chemo-
therapy with cisplatin and doxorubicin.
Tumor histopathology in the explanted liver. The
histological type was predominantly epithelial (n =
20, 57.1%), containing fetal and/or embryonal de-
rivatives in variable proportions in the majority of
cases (90%). The second most common histologic
type was mixed epithelial-stromal (42.9%; Fig 3
and Table II). Other tumor features included
SCU histological component in 12 children
(34%), median size 7 cm (range, 2.2–16), single tu-
mor in 23 children (65.7%), vascular invasion in 19
(54.3%), necrosis $50% in 18 (51.4%), hilar
lymph node invasion in 3 (8.6%), and positive mar-
gins in 3 children (8.6%). Twenty-seven patients
(77.1%) were stage III following the Children’s
Oncology Group staging system.9
Survival outcomes. The overall 1-, 3-, and 5-year
patient survival rate was 88.6%, 85.7%, and 85.7%,
respectively. The actuarial 1-, 3-, and 5-year graft
survival was 85.7%, 82.9%, and 80%, respectively.
Four deaths resulted from recurrence and/or
metastatic disease at 4, 6, 10, and 40 months after
transplantation. The sites of recurrence were the
lungs in 2, the abdomen in the third patient, and
multiple metastatic lesions, including lungs, brain,
and mediastinum in the fourth. Two patients with
lung metastases had lung disease before LTx,
which had resolved with chemotherapy. Pseudomo-
nas sepsis 12 months after LD-LTx accounted for
death in the fifth child.
Recurrent hepatoblastoma. Six children (17.1%)
presented with recurrence of the primary disease.
Table I. Demographics of 35 children who received LTx for unresectable hepatoblastoma at Children’s
Hospital of Pittsburgh (1987–2011)
Total (35) Cadaveric (n = 27) Living donor (n = 8) P value
Age at transplantation, y 3.0 ± 1.4 3.3 ± 1.4 1.8 ± 1.0 .008
Male gender, n (%) 21 (60) 17 (63) 4 (50) .685 (NS)
Time from diagnosis to LTx, mo 7.9 ± 4.6 8.6 ± 4.9 5.4 ± 1.9 .010
Weight at transplantation, kg 13.4 ± 3.9 14.2 ± 3.9 10.5 ± 2.7 .012
Donor age, y 14 ± 14.6 7.9 ±10.9 32.5 ± 5.8 <.001
Cold ischemia time, h 7.8 ± 4.0 9.4 ± 3.1 2.6 ± 1.2 <.001
Warm ischemia time, min 39.1 ± 12.2 42.1 ± 12.3 29.4 ± 5.3 <.001
Metastatic lung disease pre-LTx, n (%) 8 (22.9) 6 (22.2) 2 (25) .999 (NS)
Liver resection pretransplantation, n (%) 5 (14.2) 5 (18.5) 0 (0) .315 (NS)
Recurrence, n (%) 6 (17.1) 4 (14.8) 2 (25) .602 (NS)
AFP at time of diagnosis, ng/mL 209,604 ± 241,771 134,324 ± 172,228 444,851 ± 286,406 .002
AFP at time of transplantation, ng/mL 45,954 ± 93,291 34,828 ± 83,813 82,111 ± 118,270 .652 (NS)
Survival, mo 88.4 ± 84.3 97.5 ± 93.0 58.0 ± 32.2 .844 (NS)
Maximum size of tumor, cm 6.8 ± 3.5 6.3 ± 3.3 8.5 ± 3.7 .126 (NS)
Cadaveric grafts include 20 whole cadaveric grafts and 7 reduced-size grafts. Eight patients received left lateral segment from living donors.
AFP, Alpha-fetoprotein; LTx, liver transplantation.
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other children are currently alive after experienc-
ing recurrences in the lungs at 3 and 22 months
after LTx. The child with lung recurrence 3
months after LTx underwent successful wedge
resection but required retransplantation 33
months after LTx for cirrhosis complicating biliary
stricture due to hepatic arterial thrombosis after
primary LTx. This child remains disease-free 4.5
years after retransplantation. The second child
with solitary pulmonary nodule in the left lower
lobe required segmental resection and 2 addi-
tional cycles of chemotherapy and is disease-free
for 26 months. In this child, the explanted liver
had shown tumor protruding into the left hepatic
vein. The recurrence likely represented a tumor
embolus.
Recurrences were more frequent in children
with pre-LTx lung metastases compared with chil-
dren with hepatic disease only (50% vs 7.4%, P =
.016). All 18 patients who had $50% tumor necro-
sis after chemotherapy are disease-free (Table III).
In contrast, a third of children with <50% necrosis
developed recurrent hepatoblastoma (P = .013,
NS). Notably, small cell undifferentiated tumor his-
tology was present in nearly equal proportions of
children with and without recurrence (16.7% vs
17.4%, P = NS). Several risk factors evaluated in
previous studies or noted in the United States ex-
perience in this report, failed to achieve statistical
significance in the CHP dataset despite a trend to-
ward numerically higher incidence in children
with recurrences, compared with those who re-
mained disease-free. These included waiting timefor transplantation (14.7 ± 12.5 months vs 7.5 ±
4.6 months, P = .140, NS; Supplementary
Table 5), positive resection margins (66.7% vs
12.5%, P = .070, NS), ‘‘rescue’’ LTx (40% vs
13.3%, P = .195, NS), and the cava-sparing piggy-
back LTx procedure compared with standard LTx
(5 of 22 or 22.7% vs 1 of 13 or 7.7%, P = .377,
NS). Other variables that were not associated
with hepatoblastoma recurrences after LTx were
AFP at diagnosis or at the time of LTx, age at trans-
plant, tumor size and numbers, AFP-response de-
fined as a decrease of $99% in peak
prechemotherapy AFP levels, number of tumors,
segmental versus whole liver grafts, or positive
lymph nodes and vascular invasion (Table III).
Outcomes related to LTx. Seven of 25 children who
received LTx for unresectable hepatoblastoma
since standardization of our immunosuppressive
protocols developed hepatic artery thrombosis
during or after LTx compared with 2 of 44
children (28% vs 4.5%, P = .009, Fisher exact
test) who received LTx for nonmalignant causes
of liver failure since 2001 under identical immuno-
suppression. Only 1 of 7 children required a re-
transplantation because of complete bile duct
necrosis. Others were managed successfully with
re-exploration, thrombectomy, and infusion of
thrombolytic agents with or without revision to
an aortic interposition graft. Although within the
normal range of 140,000–400,000 per mm3, mean
platelet counts were greater in hepatoblastoma pa-
tients compared with 44 other children without
malignancy (P = .0007). No between-group differ-
ences were seen in the incidence and severity of
Table II. Gross pathology and histologic findings in 35 patients who received liver transplant for HBL at
CHP (1987–2011)
Patient Size, cm Necrosis, % Tumors, n Nodes Margins
Vascular
invasion SCU Histologic type Stage
1 7 10–15 1   + + HBL epithelial, fetal + embryonal III
2 5 >75 1   +  HBL mixed, teratoid III
3 10 <20 1  + +  HBL mixed, teratoid with anaplasia III
4 8.8 <20 1     HBL epithelial, fetal + embryonal III
5 2.2 <10 1   +  HBL epithelial, fetal + embryonal IV
6 5.5 20 1    + HBL epithelial, fetal + embryonal III
7 9 50 1   + + HBL mixed IV
8 10 90 1   +  HBL mixed, teratoid III
9 7 >95 1     HBL mixed III
10 12.5 <50 1   + + HBL mixed, teratoid IV
11 2.3 >50 >3     HBL epithelial, embryonal III
12 12 50 >3 + + +  HBL epithelial, fetal + embryonal + MT III
13 7 >95 3 na  +  HBL epithelial, embryonal III
14 7 na 1     HBL mixed IV
15 4 >95 >3   + + HBL epithelial, fetal + embryonal III
16 9 50 1     HBL mixed III
17 3 10 >3 + + +  HBL epithelial, MT IV
18 4.5 100 1     HBL epithelial, fetal III
19 5.5 <50 1    + HBL epithelial, embryonal III
20 7 95 1   +  HBL epithelial, fetal + embryonal III
21 16 <10 1   +  HBL mixed III
22 na 100 na     HBL mixed III
23 4.5 >90 >3 +  +  HBL epithelial, embryonal IV
24 5 <10 >3     HBL epithelial, fetal + embryonal III
25 15 >95 1   +  HBL mixed III
26 5 >95 1     HBL epithelial III
27 7 >95 >3   +  HBL epithelial, embryonal + fetal IV
28 2.7 na 1    + HBL mixed III
29 7.4 <50 >3   + + HBL epithelial, embryonal + fetal IV
30 4.4 50 1   +  HBL epithelial, embryonal III
31 3.5 15 >3    + HBL mixed III
32 7.0 15 1    + HBL epithelial, embryonal + SCU III
33 6.5 20 1    + HBL mixed III
34 9.0 >20 >3   + + HBL epithelial, embryonal + fetal III
35 6.7 70 1     HBL mixed III
Patients 3, 14, 17, 19, 21, and 29 presented with recurrence of HBL after transplant. Patients 5, 19, 22, 29, and 31 underwent liver resection before trans-
plantation. Largest lesion was count for tumor size.
CHP, Children’s Hospital of Pittsburgh; HBL, hepatoblastoma; MT, macrotrabecular; na, data not available; SCU, small cell undifferentiated variant.
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blood concentrations at 1, 3, 6, and 12 months af-
ter LTx (Table IV).
DISCUSSION
As suspected, our study confirms a 4-fold in-
crease in hepatoblastoma incidence in a represen-
tative sample of the general population during a
period when the 10-fold larger U.S. population
grew 38.5%. As a result, the numbers of LTx for
hepatoblastoma during the last 2 decades has
increased 20-fold, with roughly half occurring in
the last 5 years. Since 1998, hepatoblastoma has
consistently surpassed other liver malignancies forwhich LTx has been performed in children, by
nearly 3-fold in 2010 (Fig 1, C). Extrapolation of
hepatoblastoma incidence from a population sam-
ple suggests that a fifth of estimated annual new
hepatoblastoma patients in the United States re-
ceive LTx currently, compared with 5% or less in
the early 1990s. Posttransplantation survival trends
remain unaffected by this change. The impact of
LTx on hepatoblastoma may be more easily appre-
ciated if outcomes are compared with those after
surgical resection only. Such a comparison may
be best achieved through a prospective registry-
based follow-up such as the Children’s Oncology
group in the United States, and its counterparts,
Fig 3. (A) Contrast CT shows multiple enhancing liver lesions; (B) fetal type: abundant cytoplasm and small nuclei
(3200); (C) embryonal type: large nuclei and occasional rosettes (3400); (D) small cell undifferentiated type: scant
cytoplasm and open chromatin (3200).
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ternational Society of Paediatric Oncology (ie,
SIOPEL) and Pediatric Liver Unresectable Tumor
Observatory (PLUTO), in Europe.7,10,11
Although numerically greater patient survival
was observed in the CHP experience compared
with that in the entire U.S. experience, recurrence
rates were not different (17% vs 15.9%, respec-
tively, P = NS). Analysis of additional variables, as is
possible from a single-center database such as
CHP, showed that pretransplantation extrahepatic
metastases were the predominant contributor to
recurrences. Four of eight children (50%) with
previous pulmonary metastases experienced recur-
rences, compared with those without previous lung
involvement (P = .016). Because residual lung dis-
ease was absent on chest CT images performed af-
ter conclusion of chemotherapy and before LTx in
all children with metastases, more sensitive imag-
ing modalities such as PET-CT may be considered
for pre-LTx re-staging. The solitary lung lesion
which occurred 22 months after LTx and led to
successful resection and survival in a child, was de-
tected with PET-CT after multiple CT scans had
failed to reveal metastases suggested by risingAFP levels. This success also demonstrates the ben-
efit of aggressive resection of solitary metastases.
Tumor response to chemotherapy, categorized
as necrosis $50%, emerged as an important
predictor of recurrence-free survival (Table III,
P = .013), confirming some recent reports which
motivated our study. One-third of children with tu-
mor necrosis <50% in the explanted liver experi-
enced recurrences subsequently compared with
the absence of recurrences among the 18 children
with tumor necrosis $50% (P = .013, Table III).
Notably, the presence of a SCU histological compo-
nent in 12 of 35 children in our study did not en-
hance recurrence of stage III and IV tumors
treated with LTx compared with those without
this component (16.7% vs 17.4%, P = NS). Recent
studies including a meta-analysis of 40 children
with the SCU histological component have de-
scribed a greater likelihood of death due to pro-
gressive or recurrent disease.5,6 However, in this
metanalysis, 2 of 4 children remained disease-free
after LTx, compared with 2 of 16 children who re-
ceived surgical resection (50% vs 12.5%, P = .162,
NS). Disease-free post-LTx survival in our study is
also better when compared with that seen after
Table III. Factors associated with recurrence of hepatoblastoma after transplantation at Children’s Hospital
of Pittsburgh (19872011)
Variables No. patients (%) Recurrence (%) P value
Type of donor
Cadaveric 27 (77.1) 4 (14.8) .602 (NS)
Living 8 (22.9) 2 (25.0)
Type of graft
Segmental 15 (42.9) 4 (26.7) .367 (NS)
Whole 20 (57.1) 2 (10.0)
Transplantation technique
Standard 13 (37.1) 1 (7.7) .377 (NS)
Piggyback (cavasparing) 22 (62.9) 5 (22.7)
Type of transplantation
Primary 30 (85.7) 4 (13.3) .195 (NS)
Rescue 5 (14.3) 2 (40)
Age at transplantation, y
#2.7 (median age at Tx) 18 (51.4) 4 (22.2) .658 (NS)
>2.7 (median age at Tx) 17 (48.6) 2 (11.8)
AFP response*
Nonresponse 25 (75.8) 4 (16) .999 (NS)
Response 8 (24.2) 1 (12.5)
AFP at time of diagnosis, ng/mL*
#100,000 (median AFP) 16 (48.5) 3 (18.8) .656 (NS)
>100,000 (median AFP) 17 (51.5) 2 (11.8)
AFP at time of transplant, ng/mL*
#2,381.5 (median AFP) 17 (50.0) 2 (11.8) .999 (NS)
>2,381.5 (median AFP) 17 (50.0) 3 (17.6)
Pulmonary metastasis at diagnosis
No 27 (77.1) 2 (7.4) .016y
Yes 8 (22.9) 4 (50.0)
Number of nodules*
Single 23 (67.6) 4 (17.4) .999 (NS)
Multiples 11 (32.4) 2 (18.2)
Nodes*
Negative 31 (91.2) 5 (16.1) .453 (NS)
Positive 3 (8.8) 1 (33.3)
Small cell undifferentiated variant
No 23 (65.7) 4 (17.4) 1.000 (NS)
Yes 12 (34.3) 2 (16.7)
Margins
Negative 32 (91.4) 4 (12.5) .070 (NS)
Positive 3 (8.6) 2 (66.7)
Vascular invasion
Yes 19 (54.3) 4 (21.1) .666 (NS)
No 16 (45.7) 2 (12.5)
Necrosis*
<50% 15 (42.8) 5 (33.3) .013y
$50% 18 (51.4) 0 (0)
Maximum size of tumor, cm
#7 (median size) 18 (51.4) 2 (11.1) .402 (NS)
>7 (median size) 17 (48.6) 4 (23.5)
*Data not available for all 35 patients.
ySignificant.
AFP response was defined as a drop of more than 99% in peak AFP levels before chemotherapy.
AFP, Alphafetoprotein; NS, not significant; Tx, transplantation.
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83% vs 2 of 16 or 12.5%, P = .025). Therefore, LTx
should be considered in the presence of the SCUcomponent, especially if microscopic synchronous
liver involvement cannot be excluded. In the afore-
mentioned metanalysis, the majority, or 10 of 16
Table IV. Hepatic artery thrombosis, platelet count, ACR, and immunosuppressant doses in children with
LTx for hepatoblastoma and nonmalignant indications at Children’s Hospital of Pittsburgh (20012011)
Hepatoblastoma (n = 25) Nonmalignant indications (n = 44) P value
Hepatic artery thrombosis, n (%) 7 (28) 2 (4.55%) .0089
Platelet count preLTx, 1,000/mm3 326 ± 199 146 ± 106 .0007
ACR <90 days postLTx
Total, n (%) 8 (32) 13 (29.55) 1.000 (NS)
Steroidsensitive, n (%) 7 (28) 12 (27.27) 1.000 (NS)
Steroidresistant, n (%) 1 (4) 1 (2.27) 1.000 (NS)
Days after Tx 34.03 ± 26.06 21.55 ± 15.38 .25 (NS)
Median FK levels postLTx, ng/mL
1 month 12.66 ± 5.18 10.68 ± 4.32 .130 (NS)
3 month 9.03 ± 6.00 8.77 ± 4.85 .864 (NS)
6 month 7.80 ± 4.67 7.40 ± 3.32 .728 (NS)
1 year 4.86 ± 2.25 5.81 ± 3.19 .206 (NS)
Steroid dose postLTx, mg
1 month 10.53 ± 7.62 14.36 ± 10.19 .130 (NS)
3 month 6.15 ± 6.26 4.63 ± 3.63 .430 (NS)
6 month 6.34 ± 7.31 4.79 ± 6.86 .479 (NS)
1 year 5.75 ± 5.53 5.58 ± 6.01 .944 (NS)
Values are mean ± SD unless otherwise noted.
ACR, Acute cellular rejection; FK, tacrolimus; LTx, liver transplantation; NS, not significant.
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component were free of obvious residual disease,
positive margins, or tumor spillage. ‘‘Rescue’’ trans-
plantation, AFP at diagnosis or before LTx, size
and number of tumors, and vascular invasion
were not significant.10,12-14
An unexpected finding is a lower recurrence rate
with cadaveric whole liver grafts compared with
segmental grafts from cadaveric or living donors in
the U.S. experience with LTx for hepatoblastoma (P
= .049). This trend is mirrored in the CHP experi-
ence with 35 children, where recurrence rates are
greater with segmental grafts (26.7% vs 10%), and
with the cava-sparing hepatectomy (22.7% vs
7.7%), whose application has been extended from
segmental LTx to whole LTx at increasing numbers
of centers. Lack of statistical significance is likely ex-
plained by the modest single-center sample size. Be-
cause the technical preference for the cava-sparing
approach is not recorded in the UNOS database,
these findings must be re-evaluated prospectively
with more detailed technical data. If confirmed,
LTx listingpoliciesmay need to evolve further to sup-
port timely access to whole liver grafts. Alternatively,
if segmental LTx is the only option to remove the un-
resectable tumor soon after chemotherapy, fewer tu-
mor cells may be dislodged into the circulation if
manipulation of the diseased liver, which occurs dur-
ing controlled ligation anddivision of caval branches
to the diseased liver during cava-sparing hepatec-
tomy, is reduced to a minimum. One approach maybe to transect caval branches sharply immediately af-
ter ligation of hilar inflow vessels and application of
upper and lower caval clamps. At least one of the
lung recurrences described previously, 22months af-
ter LTx, may have occurred because of embolization
of tumor protruding into the upper vena cava.
The effects of chemotherapy on post-LTx sur-
vival cannot be evaluated in our CHP experience
because nearly all children received 4 cycles before
and 2 cycles after LTx. Sepsis accounted for up to
one-fifth of deaths after LTx for hepatoblastoma in
non-CHP and CHP patients, attesting to the com-
bined immunosuppressive toxicity of anti-rejection
and anti-tumor therapy. Therefore, early minimi-
zation of antirejection medications is a reasonable
strategy for this unique population and has been
advocated previously.15,16 A cautious approach is
still necessary because under conditions of identi-
cal immunosuppression, the incidence of rejection
was similar when children who received LTx for he-
patoblastoma were compared with children who
underwent transplantation for nonmalignant
indications. Further, 3 of 31 graft losses in the
UNOS database were related to rejection
(Supplementary Table 4).
We also report for the first time, a 6-fold greater
incidence of hepatic arterial thrombosis after LTx
for hepatoblastoma compared with nonmalignant
indications (P = .0089). Thrombotic graft failure
was the single largest category of graft failure re-
quiring retransplantation in the United States
Surgery
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only 1 of 7 events occurred in children with seg-
mental grafts, which are more prone to technical
complications.17,18 The remaining 6 events were
seen with whole liver grafts. Ultrasounds after
LTx allowed successful early intervention with
thrombectomy and without a retransplant proce-
dure in all but one hepatic arterial thrombosis,
with excellent graft function. Thrombocytosis fre-
quently accompanies hepatoblastoma, and is at-
tributed to overproduction of thrombopoietin,
the major physiological regulator of thrombopoie-
sis, by tumor cells.19,20 Although platelet counts
were significantly greater in children with hepato-
blastoma at the time of LTx, mean counts were
within the normal range in both groups suggest-
ing other explanations for a procoagulant state.
More importantly, cisplatin, the main chemother-
apeutic agent for the treatment of hepatoblas-
toma, increases procoagulant activity of red
blood cells via activation of extrinsic and intrinsic
coagulation pathways.21 Given this propensity for
thromboses, we routinely initiate an antiplatelet
agent such as aspirin immediately before LTx,
and continue short-term post-LTx anticoagulation
with heparin.
The data reported here have been supplied by the
United Network for Organ Sharing as the contractor for
the Organ Procurement and Transplantation Network.
The interpretation and reporting of these data are the
responsibility of the authors and in no way should be
seen as an official policy of or interpretation by the
OPTN or the US government. We would like to thank Ms
Dale Zecca and Ms Lillian Martin for their assistance
during the preparation of this manuscript.REFERENCES
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